Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

International Journal of Obesity volume 38, pages 163–169 (2014)Cite this article

Subjects

Abstract

Obesity is one of the greatest public health challenges of the 21st century. Obesity is currently responsible for ∼0.7–2.8% of a country’s health costs worldwide. Treatment is often not effective because weight regulation is complex. Appetite and energy control are regulated in the brain. Melanocortin-4 receptor (MC4R) has a central role in this regulation. MC4R defects lead to a severe clinical phenotype with lack of satiety and early-onset severe obesity. Preclinical research has been carried out to understand the mechanism of MC4R regulation and possible effectors. The objective of this study is to systematically review the literature for emerging pharmacological obesity treatment options. A systematic literature search was performed in PubMed and Embase for articles published until June 2012. The search resulted in 664 papers matching the search terms, of which 15 papers remained after elimination, based on the specific inclusion and exclusion criteria. In these 15 papers, different MC4R agonists were studied in vivo in animal and human studies. Almost all studies are in the preclinical phase. There are currently no effective clinical treatments for MC4R-deficient obese patients, although MC4R agonists are being developed and are entering phase I and II trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Withrow D, Alter DA . The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011; 12: 131–141.

    Article  CAS  PubMed  Google Scholar 

  2. Skidmore PM, Yarnell JW . The obesity epidemic: prospects for prevention. QJM 2004; 97: 817–825.

    Article  CAS  PubMed  Google Scholar 

  3. Qi L, Cho YA . Gene-environment interaction and obesity. Nutr Rev 2008; 66: 684–694.

    Article  PubMed  Google Scholar 

  4. Moore CJ, Cunningham SA . Social position, psychological stress, and obesity: a systematic review. J Acad Nutr Diet 2012; 112: 518–526.

    Article  PubMed  Google Scholar 

  5. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS . Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68–100.

    CAS  PubMed  Google Scholar 

  6. Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A et al. Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem 2008; 51: 1026–1034.

    Article  CAS  PubMed  Google Scholar 

  7. van den Berg L, Glorie-Docter M, van den Akker E, Delemarre-van de Waal HA . Obesity caused by melanocortin-4 receptor mutations. Ned Tijdschr Geneeskd 2012; 156: A4548.

    PubMed  Google Scholar 

  8. Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther 2010; 335: 520–532.

    Article  CAS  PubMed  Google Scholar 

  9. Farooqi IS . Monogenic human obesity. Front Horm Res 2008; 36: 1–11.

    CAS  PubMed  Google Scholar 

  10. Hansen MJ, Schioth HB, Morris MJ . Feeding responses to a melanocortin agonist and antagonist in obesity induced by a palatable high-fat diet. Brain Res 2005; 1039: 137–145.

    Article  CAS  PubMed  Google Scholar 

  11. Getting SJ . Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006; 111: 1–15.

    Article  CAS  PubMed  Google Scholar 

  12. Ye Z, MacNeil T, Weinberg DH, Kalyani RN, Tang R, Strack AM et al. Structure-activity relationship of linear tetrapeptides Tic-DPhe-Arg-Trp-NH2 at the human melanocortin-4 receptor and effects on feeding behaviors in rat. Peptides 2005; 26: 2017–2025.

    Article  CAS  PubMed  Google Scholar 

  13. He S, Ye Z, Dobbelaar PH, Sebhat IK, Guo L, Liu J et al. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity. Bioorg Med Chem Lett 2010; 20: 4399–4405.

    Article  CAS  PubMed  Google Scholar 

  14. He S, Ye Z, Dobbelaar PH, Bakshi RK, Hong Q, Dellureficio JP et al. Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity. Bioorg Med Chem Lett 2010; 20: 6524–6532.

    Article  CAS  PubMed  Google Scholar 

  15. Krishna R, Gumbiner B, Stevens C, Musser B, Mallick M, Suryawanshi S et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009; 86: 659–666.

    Article  CAS  PubMed  Google Scholar 

  16. Hong Q, Bakshi RK, Palucki BL, Park MK, Ye Z, He S et al. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Bioorg Med Chem Lett 2011; 21: 2330–2334.

    Article  CAS  PubMed  Google Scholar 

  17. Benoit SC, Schwartz MW, Lachey JL, Hagan MM, Rushing PA, Blake KA et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci 2000; 20: 3442–3448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Conde-Frieboes K, Ankersen M, Breinholt J, Hansen BS, Raun K, Thogersen H et al. Serendipitous discovery of a new class of agonists for the melanocortin 1 and 4 receptors and a new class of cyclophanes. Bioorg Med Chem Lett 2011; 21: 1459–1463.

    Article  CAS  PubMed  Google Scholar 

  19. Al-Barazanji KA, Miller JE, Rice SQ, Arch JR, Chambers JK . C-terminal fragments of ACTH stimulate feeding in fasted rats. Horm Metab Res 2001; 33: 480–485.

    Article  CAS  PubMed  Google Scholar 

  20. Cepoi D, Phillips T, Cismowski M, Goodfellow VS, Ling N, Cone RD et al. Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis. Brain Res 2004; 1000: 64–71.

    Article  CAS  PubMed  Google Scholar 

  21. Chen C, Jiang W, Tran JA, Tucci FC, Fleck BA, Markison S et al. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2008; 18: 129–136.

    Article  CAS  PubMed  Google Scholar 

  22. Kumar KG, Sutton GM, Dong JZ, Roubert P, Plas P, Halem HA et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides 2009; 30: 1892–1900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hsiung HM, Hertel J, Zhang XY, Smith DP, Smiley DL, Heiman ML et al. A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats. Endocrinology 2005; 146: 5257–5266.

    Article  CAS  PubMed  Google Scholar 

  24. Hsiung HM, Smiley DL, Zhang XY, Zhang L, Yan LZ, Craft L et al. Potent peptide agonists for human melanocortin 3 and 4 receptors derived from enzymatic cleavages of human beta-MSH(5-22) by dipeptidyl peptidase I and dipeptidyl peptidase IV. Peptides 2005; 26: 1988–1996.

    Article  CAS  PubMed  Google Scholar 

  25. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW . MT-II induces penile erection via brain and spinal mechanisms. Ann N Y Acad Sci 2003; 994: 90–95.

    Article  CAS  PubMed  Google Scholar 

  26. Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013; 62: 490–497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Linde Y, Ovadia O, Safrai E, Xiang Z, Portillo FP, Shalev DE et al. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers 2008; 90: 671–682.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Granell S, Mohammad S, Ramanagoudr-Bhojappa R, Baldini G . Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol Endocrinol 2010; 24: 1805–1821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ward KR, Bardgett JF, Wolfgang L, Stocker SD . Sympathetic response to insulin is mediated by melanocortin 3/4 receptors in the hypothalamic paraventricular nucleus. Hypertension 2011; 57: 435–441.

    Article  CAS  PubMed  Google Scholar 

  30. Roubert P, Dubern B, Plas P, Lubrano-Berthelier C, Alihi R, Auger F et al. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. J Endocrinol 2010; 207: 177–183.

    Article  CAS  PubMed  Google Scholar 

  31. Raun K, Dahl K, Nilsson C, Voss PV, Fosgerau K, Conde-Frieboes KW et al. Novel MC4 agonist peptide effectively reduces body weight in diet-induced obese rats and minipigs. Obesity 2011; 19: S179.

    Article  Google Scholar 

  32. Raun K, Conde-Frieboes KW, Sensfuss U, Wulff BS . A long acting, selective MC4 receptor agonist effectively reduces appetite and bodyweight in diet induced obese rats. Obes Rev 2011; 12: 279.

    Google Scholar 

  33. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C . The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577–1579.

    Article  CAS  PubMed  Google Scholar 

  34. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245–256.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. L Fani and S Bak: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pediatrics, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands

    L Fani, S Bak & E L T van den Akker

  2. Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands

    P Delhanty & E F C van Rossum

Authors
  1. L Fani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Bak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Delhanty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E F C van Rossum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E L T van den Akker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E L T van den Akker.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fani, L., Bak, S., Delhanty, P. et al. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes 38, 163–169 (2014). https://doi.org/10.1038/ijo.2013.80

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2013.80

Keywords

This article is cited by

Search

Advanced search

Quick links